B. Richard

发表

C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.

J. Rossi, B. Klein, M. Picot, 1998, Leukemia & lymphoma.

Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

L. Mannone, P. Fenaux, N. Vey, 2011, Annals of Hematology.

Evaluation of Imipenem 1.5 g Daily in Febrile Patients with Short Duration Neutropenia After Chemotherapy for Non-leukemic Hematologic Malignancies and Solid Tumors: Personal Experience and Review of the Literature

P. Fabbro-Péray, E. Jourdan, A. Sotto, 2003, Leukemia & lymphoma.

Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder

E. Jourdan, A. Sotto, J. Jourdan, 2003, Leukemia & lymphoma.

[Reversible cardiomyopathy induced by interferon].

J. Jourdan, C. Barbuat, B. Richard, 1993, Therapie.

High‐dose cytosine arabinoside and mitoxantrone in previously‐treated acute leukemia patients

D. Maraninchi, D. Sainty, Y. Carcassonne, 1990, European journal of haematology.

Prospective Randomized Study Comparing MEMID with a Chop-Like Regimen in Elderly Patients with Aggressive Non-Hodgkin’s Lymphoma

F. Peyrade, E. Chamorey, C. Foussard, 2005, Oncology.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, A. Stamatoullas, B. Quesnel, 2000, Haematologica.

Ga-67 in Castleman's disease.

J. Alberini, J. Devaux, F. Tenenbaum, 2003, Clinical nuclear medicine.